Cargando…
The CD44high Subpopulation of Multifraction Irradiation-Surviving NSCLC Cells Exhibits Partial EMT-Program Activation and DNA Damage Response Depending on Their p53 Status
Ionizing radiation (IR) is used for patients diagnosed with unresectable non-small cell lung cancer (NSCLC). However, radiotherapy remains largely palliative due to the survival of specific cell subpopulations. In the present study, the sublines of NSCLC cells, A549IR (p53wt) and H1299IR (p53null) s...
Autores principales: | Pustovalova, Margarita, Alhaddad, Lina, Blokhina, Taisia, Smetanina, Nadezhda, Chigasova, Anna, Chuprov-Netochin, Roman, Eremin, Petr, Gilmutdinova, Ilmira, Osipov, Andreyan N., Leonov, Sergey |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7956695/ https://www.ncbi.nlm.nih.gov/pubmed/33673439 http://dx.doi.org/10.3390/ijms22052369 |
Ejemplares similares
-
IR-Surviving NSCLC Cells Exhibit Different Patterns of Molecular and Cellular Reactions Relating to the Multifraction Irradiation Regimen and p53-Family Proteins Expression
por: Alhaddad, Lina, et al.
Publicado: (2021) -
The p53–53BP1-Related Survival of A549 and H1299 Human Lung Cancer Cells after Multifractionated Radiotherapy Demonstrated Different Response to Additional Acute X-ray Exposure
por: Pustovalova, Margarita, et al.
Publicado: (2020) -
CD44+ and CD133+ Non-Small Cell Lung Cancer Cells Exhibit DNA Damage Response Pathways and Dormant Polyploid Giant Cancer Cell Enrichment Relating to Their p53 Status
por: Pustovalova, Margarita, et al.
Publicado: (2022) -
Polyploid/Multinucleated Giant and Slow-Cycling Cancer Cell Enrichment in Response to X-ray Irradiation of Human Glioblastoma Multiforme Cells Differing in Radioresistance and TP53/PTEN Status
por: Alhaddad, Lina, et al.
Publicado: (2023) -
Spontaneous γH2AX foci in human dermal fibroblasts in relation to proliferation activity and aging
por: Zorin, Vadim, et al.
Publicado: (2019)